Homologous targeting NIR-II fluorescence imaging nano-platform, preparation method thereof and application of homologous targeting NIR-II fluorescence imaging nano-platform in tumor imaging
Through CsLu(1-x-y)YbxEryFz nanoparticles covering the cancer cell membrane, the problems of low resolution of existing NIR-I region fluorescence imaging technology and poor stability of traditional NIR-II region probes are solved, achieving high resolution , long-lived NIR-II region fluorescence imaging and tumor targeting effects.
Patent Information
- Application Number
- CN202410808344.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-21
AI Technical Summary
The existing NIR-I region fluorescence imaging technology is subject to light scattering, light absorption and biological tissue autofluorescence interference, resulting in low imaging spatial resolution, signal background ratio and limited penetration depth, and the traditional NIR-II region fluorescence probe has an emission bandwidth Large, poor photobleaching and stability, as well as inherent toxicity, limit their application.
CsLu(1-x-y)YbxEryFz nanoparticles are used as the luminescence center, and the cancer cell membrane is coated by extrusion method to form a homologous targeting NIR-II region fluorescence imaging nanoplatform, and the immune escape and tumor targeting of the cancer cell membrane are used to improve the nanometers. Particle stability and targeting ability.
Achieve high-resolution NIR-II region fluorescence imaging, enhances signal-to-noise ratio and penetration depth, has a longer luminescence lifetime and light stability, can accurately guide the resection of tumor tissue, and has better water stability and Biocompatibility.
Smart Images

Figure CN118903477A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of NIR-II region fluorescence imaging, and in particular relates to a NIR-II fluorescence imaging probe and a preparation method and application thereof. Background Art
[0002] Specific imaging diagnosis is of great significance for the early detection of tumors and the study of tumor metastasis. Among the many imaging methods, fluorescence imaging is one of the most powerful imaging techniques in biological research and clinical applications. However, fluorescence imaging in the NIR-I region is interfered by light scattering, light absorption and autofluorescence of biological tissues, resulting in low imaging spatial resolution, signal-to-background ratio (SBR) and limited penetration depth. In order to overcome the limitations of fluorescence imaging in the NIR-I region, optical simulation predictions show that the near-infrared second window (NIR-II, 1000-1700nm) is more conducive to fluorescence imaging. In addition to the further reduction of the scattering coefficient at a fixed tissue depth, the tissue autofluorescence in the NIR-II region decreases exponentially and is almost zero when the wavelength exceeds ≈1500nm. Although various biological tissues have slightly higher light absorption in the NIR-II region than in the NIR-I region, fluorescence imaging in the NIR-II region has higher spatial resolution, signal-to-noise ratio and penetration depth when scattering loss is reduced and autofluorescence is close to zero. Therefore, fluorescence imaging in the NIR-II region is becoming a rapidly developing field.
[0003] In recent years, researchers have developed various types of NIR-II region fluorescence imaging probes, such as carbon nanotubes (CNTs), organic fluorophores, semiconductor quantum dots (QDs) (such as PbSe and AgS), etc. However, carbon nanotubes generally exhibit a wide emission band (>300nm) and low quantum yield (QY) (0.1-0.4%), which hinders their practical application. For organic fluorophores, photobleaching and poor stability limit their application. In addition, semiconductor quantum dots also have some inevitable problems, such as light flickering or the inherent toxicity of heavy metal elements (such as Pb and Cd). Therefore, there is an urgent need to find new NIR-II region fluorescent nanoprobes to overcome the inherent limitations of traditional nanoprobes.
[0004] The trivalent lanthanide ions (Ln 3+ ) has an electronic configuration of 4f n 5s 2 5p 6 (n=1-13), due to Ln 3+ The rich energy levels make its emission cover the visible and NIR regions. It is reported that some Ln 3+ Ions (such as Yb 3+ 、Tm 3+ , Er 3+ 、Ho3+ 、Dy 3 + 、Sm 3+ 、Nd 3+ and Pr 3+ ) can produce fluorescence emission in the NIR-II region, and the down-conversion luminescence of rare earth ions has a large Stokes shift and a narrow emission half-peak width, showing great application potential in fluorescence imaging. 3+ , Er 3 + Introduced into CsLu (1-x-y) Yb x Er y F z The high-intensity NIR-II fluorescence is obtained in the matrix for surgical navigation.
[0005] After entering the blood, nanoparticles are easily recognized and cleared by the reticuloendothelial system or mononuclear phagocytes in the immune system. In addition, nonspecific proteins and biomolecules can easily adhere to the surface of nanoparticles, further interfering with the interaction between nanoparticles and biological systems. During fluorescence imaging, nanoparticles can usually achieve nonspecific targeting under the action of enhanced permeability and retention (EPR) in vivo, but the targeting efficiency is low. Therefore, after preparing nanomaterials, it is very important to further construct active targeting nanoparticles. Cell membranes can give nanoparticles unique biological properties. By fusing cell membranes to the surface of drug nanoparticles, nanoparticles can have the properties of the original cell membrane and improve the stability of nanoparticles. Among different types of cell membranes, cancer cell membranes have immune escape capabilities and tumor active targeting capabilities. Coating cancer cell membranes on the surface of nanoparticles can give them active targeting capabilities. Summary of the invention
[0006] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.
[0007] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.
[0008] Therefore, the purpose of the present invention is to overcome the deficiencies in the prior art and provide a homologous targeted NIR-II region fluorescence imaging nanoplatform.
[0009] In order to solve the above technical problems, the present invention provides the following technical solutions: comprising:
[0010] CsLu (1-x-y) Ybx Er y F z The nanoparticles are the luminescent centers. After being treated to be water-soluble, the cancer cell membrane is coated on their surface by extrusion, thus forming a homologous targeted NIR-II region fluorescence imaging nanoplatform.
[0011] Among them, the CsLu (1-x-y) Yb x Er y F z In the nanoparticles, the value of x is 0-0.98, the value of y is 0.02-0.98, and the value of z is 4-7.
[0012] As a preferred embodiment of the homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, wherein: the cancer cell membrane is (1-x-y) Yb x Er y F z The mass ratio of the nanoparticles is 0.5 to 2:1.
[0013] As a preferred embodiment of the homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, the cancer cell membrane includes mouse breast cancer cell membrane and mouse colon cancer cell membrane.
[0014] Another object of the present invention is to provide a method for preparing a homologous targeted NIR-II region fluorescence imaging nanoplatform.
[0015] In order to solve the above technical problems, the present invention provides the following technical solutions: comprising:
[0016] Lu salt, Yb salt, Er salt, Cs2CO3, oleic acid, oleylamine and octadecene were mixed and heated under vacuum conditions to form a transparent solution, kept warm under argon atmosphere, then cooled to room temperature, NH4F was added for synthesis reaction, and washed after the reaction to obtain CsLu (1-x-y) Yb x Er y F z Nanoparticles, the CsLu (1-x-y) Yb x Er y F z In the nanoparticles, the value of x ranges from 0 to 0.98, the value of y ranges from 0.02 to 0.98, and the value of z ranges from 4 to 7;
[0017] LqCy (1-x-y) Yb x Er y F z The nanoparticles are dissolved in a nonpolar or medium polar solvent, to which NH2-PEG dissolved in water is added. 2000-DSPE, ultrasonic mixing, to obtain water-soluble CsLu (1-x-y) Yb x Er y F z Nanoparticles;
[0018] The extracted cancer cell membrane was mixed with CsLu (1-x-y) Yb x Er y F z The nanoparticles were mixed in PBS, sonicated in a water bath, and repeatedly extruded by an extruder to obtain a homologous targeted NIR-II region fluorescence imaging nanoplatform.
[0019] As a preferred solution of the method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, wherein: the salt includes Ac salt or Cl salt.
[0020] As a preferred scheme for the preparation method of the homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, the molar ratio of the Yb salt to the Er salt is 9-19:1-5, and the molar ratio of the Lu salt, Cs2CO3, and NH4F is 1-4:1-3:5-14.
[0021] As a preferred embodiment of the method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, when the amount of oleic acid is 6-15 mL, the corresponding amount of oleylamine is 0-4 mL, and the amount of octadecene is 10-15 ml.
[0022] As a preferred solution of the method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, the reaction temperature of the synthesis reaction is 285° C. to 315° C., and the reaction time is 45 to 60 min.
[0023] As a preferred embodiment of the method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, the non-polar or medium-polar solvent comprises one of acetone, tetrahydrofuran and cyclohexane.
[0024] Another object of the present invention is to provide a homologous targeted NIR-II region fluorescence imaging nanoplatform for use in tumor imaging.
[0025] Beneficial effects of the present invention:
[0026] The present invention combines CsLu (1-x-y) Yb x Er y F z Based on the NIR-II luminescence performance of nanoparticles and the good immune escape and tumor targeting of cancer cell membranes, we designed CsLu coated with cancer cell membranes.(1-x-y) Yb x Er y F z Nanoparticles are used to perform NIR-II fluorescence imaging of tumors and guide surgical removal of tumors;
[0027] Compared with the existing visible region and NIR-I region fluorescent materials, the present invention has a fluorescence emission peak in the NIR-II region, which is conducive to high-resolution near-infrared fluorescence imaging, thereby accurately guiding tumor tissue resection;
[0028] Compared with organic materials, the present invention has a longer luminescence lifetime, higher light stability and biocompatibility, and is not easily photobleached.
[0029] Compared with other targeting materials, such as hyaluronic acid (HA), polypeptides, etc., the cancer cell membrane of the present invention has the unique immune escape ability and homologous binding ability of cancer cells, and has better coating effect and better water stability, so that it has a better accumulation effect in tumor tissue. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:
[0031] Figure 1 This is a flow chart for constructing a homologous targeted NIR-II region fluorescence imaging nanoplatform according to Example 1 of the present invention.
[0032] Figure 2 CsLu obtained in Example 1 of the present invention (1-x-y) Yb x Er y F z Transmission electron microscopy (TEM) image of the nanoparticles.
[0033] Figure 3 CsLu obtained in Example 1 of the present invention (1-x-y) Yb x Er y F z Fluorescence spectra of nanoparticles.
[0034] Figure 4 This is a diagram showing the result of using the homologous targeted NIR-II fluorescence imaging nanoplatform obtained in Example 1 of the present invention to guide surgical removal of tumors.
[0035] Figure 5 CsLu obtained in Example 2 of the present invention(1-x-y) Yb x Er y F z Fluorescence spectra of nanoparticles.
[0036] Figure 6 CsLu obtained in Example 3 of the present invention (1-x-y) Yb x Er y F z Fluorescence spectra of nanoparticles.
[0037] Figure 7 CsLu obtained in Example 4 of the present invention (1-x-y) Yb x Er y F z Fluorescence spectra of nanoparticles.
[0038] Figure 8 CsLu obtained by using different amounts of Yb(Ac)3 in Example 5 of the present invention (1-x-y) Yb x Er y F z Fluorescence spectra of nanoparticles.
[0039] Fig. 9 CsLu obtained by using different Er(Ac)3 dosages in Example 5 of the present invention (1-x-y) Yb x Er y F z Fluorescence spectra of nanoparticles.
[0040] Fig.10 CsLu obtained by different ratios of Ln(Ac)3:Cs2CO3:NH4F in Example 6 of the present invention (1-x-y) Yb x Er y F z Fluorescence spectra of nanoparticles.
[0041] Fig.11 CsLu obtained at different high temperature insulation temperatures in Example 7 of the present invention (1-x-y) Yb x Er y F z Transmission electron microscopy (TEM) image of the nanoparticles. DETAILED DESCRIPTION
[0042] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.
[0043] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.
[0044] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor does it refer to a separate or selective embodiment that is mutually exclusive with other embodiments.
[0045] Unless otherwise specified, the raw materials used in the present invention are all commercially available in the art.
[0046] Example 1
[0047] Reference Figure 1 , is a method for constructing a homologous targeted NIR-II region fluorescence imaging nanoplatform of the present invention, specifically:
[0048] 1) 0.02mmol Er(Ac)3, 0.18mmol Yb(Ac)3, 0.8mmol Lu(Ac)3 and 0.25mmol Cs2CO3 were added to a three-necked flask containing 6mL oleic acid, 2mL oleylamine and 6mL octadecene, and the mixture was heated to 120°C under vacuum until a transparent solution was formed, then kept warm for 30min under argon atmosphere, then cooled to room temperature, 3.5mmol NH4F was added, and the mixture was heated to 300°C under vacuum, kept warm for 45min under argon atmosphere, then cooled to room temperature, excess ethanol was added, and centrifuged at 10000rpm for 15min, the supernatant was removed and washed with ethanol 3 times to obtain CsLu of this example. (1-x-y) Yb x Er y F z Nanoparticles; the obtained nanoparticles have a size and have a NIR-II region fluorescence of 1530nm, Figure 2 For its TEM image, Figure 3 Its fluorescence spectrum.
[0049] 2) CsLu (1-x-y) Yb x Er y F z The nanoparticles were dissolved in cyclohexane to obtain 10 mg / mL CsLu (1-x-y) Yb x Er y F zSolution, with 20 mg / mL NH2-PEG 2000 -DSPE aqueous solution was mixed with ultrasound for 10 min, centrifuged at 15000 rpm for 5 min, and washed with ultrapure water to obtain water-soluble CsLu (1-x-y) Yb x Er y F z Nanoparticles.
[0050] 3) After incubating mouse breast cancer cells (4T1) in a cell culture flask for 48 hours, the cells were separated from the flask wall using a cell scraper, the cells were collected by centrifugation and washed with PBS, and the cells were recollected by centrifugation. According to the method in the reagent manual, the cell pellet was suspended in a hypotonic lysis buffer containing a membrane protein extraction reagent and kept in an ice water bath for 10-15 minutes. The above cells were broken by repeated freezing and thawing, and the broken materials were collected by centrifugation (6000g, 10min, 4°C), and the supernatant was retained. Finally, the cell membrane fragments were collected by centrifugation (14000g, 30min, 4°C), freeze-dried, and stored in a -80°C refrigerator for later use.
[0051] 4) 5 mg cell membrane fragments and 10 mg water-soluble CsLu (1-x-y) Yb x Er y F z The nanoparticles were mixed into 10 mL of PBS, sonicated in a water bath for 5 min, and repeatedly extruded 5 times using an extruder. Finally, the obtained nanoparticles were freeze-dried to construct a homologous targeted NIR-II fluorescence imaging nanoplatform, which was stored in a -80°C refrigerator for future use.
[0052] Application Testing
[0053] The NIR-II region fluorescence imaging nanoplatform prepared in Example 1 is used to guide surgery to remove tumors, and the specific steps are as follows:
[0054] 200 μL of 20 mg / mL NIR-II fluorescence imaging nanoplatform material was injected into mice through the tail vein. The mice were anesthetized using a small animal inhalation gas anesthesia machine 12 hours after injection. After anesthesia, the mice were placed in the NIR-II fluorescence imaging instrument for fluorescence imaging. The tumor margin was marked by NIR-II fluorescence imaging and the tumor was removed under anesthesia.
[0055] The results are as follows Figure 4 As shown, Figure 4These are the renderings before (left) and after (right) surgical removal of the tumor. The illustration on the right is the image after partial removal of the tumor. From the images, it can be seen that the fluorescence of the tumor edge and the tumor site disappears after tumor removal, and the removed tumor tissue shows two-zone fluorescence under the imager, thus proving that the material can guide the removal of the tumor.
[0056] Example 2
[0057] The difference from Example 1 is that the CsLu in step 1) is adjusted (1-x-y) Yb x Er y F z The dosage of Er(Ac)3, Yb(Ac)3 and Lu(Ac)3 in the preparation of nanoparticles is as follows:
[0058] 0.02mmol Er(Ac)3, 0.38mmol Yb(Ac)3, 0.6mmol Lu(Ac)3 and 0.25mmol Cs2CO3 were added to a three-necked flask containing 8mL oleic acid and 6mL octadecene, and the mixture was heated to 120°C under vacuum until a transparent solution was formed, then kept warm for 30min under argon atmosphere, then cooled to room temperature, 6mmol NH4F was added, and the mixture was heated to 310°C under vacuum, kept warm for 45min under argon atmosphere, then cooled to room temperature, added with excess ethanol, centrifuged at 9000rpm for 15min, removed the supernatant and washed with cyclohexane 3 times to obtain CsLu in this example. (1-x-y) Yb x Er y F z Nanoparticles, the obtained nanoparticles have a size and a NIR-II region fluorescence of 1530nm, Figure 5 Its fluorescence spectrum.
[0059] Example 3
[0060] The difference from Example 1 is that the CsLu in step 1) is adjusted (1-x-y) Yb x Er y F z The dosage of Er(Ac)3, Yb(Ac)3 and Lu(Ac)3 in the preparation of nanoparticles is as follows:
[0061] 0.02mmol Er(Ac)3, 0.78mmol Yb(Ac)3, 0.2mmol Lu(Ac)3 and 0.25mmol Cs2CO3 were added to a three-necked flask containing 10mL oleic acid, 4ml oleylamine and 6mL octadecene, and the mixture was heated to 120°C under vacuum until a transparent solution was formed, then kept warm for 30min under argon atmosphere, then cooled to room temperature, 3.25mmol NH4F was added, and the mixture was heated to 285°C under vacuum, kept warm for 45min under argon atmosphere, then cooled to room temperature, added with excess ethanol, centrifuged at 12000rpm for 15min, removed the supernatant and washed with ethanol and acetone three times in sequence to obtain CsLu of this example. (1-x-y) Yb x Er y F z Nanoparticles, the obtained nanoparticles have a size and a NIR-II region fluorescence of 1530nm, Figure 6 Its fluorescence spectrum.
[0062] Example 4
[0063] The difference from Example 1 is that the CsLu in step 1) is adjusted (1-x-y) Yb x Er y F z The dosage of Er(Ac)3, Yb(Ac)3 and Lu(Ac)3 in the preparation of nanoparticles is as follows:
[0064] 0.02mmol Er(Ac)3, 0.98mmol Yb(Ac)3, and 1mmol Cs2CO3 were added to a three-necked flask containing 15mL oleic acid, 3ml oleylamine, and 6mL octadecene. The mixture was heated to 120°C under vacuum until a transparent solution was formed, then kept warm for 30min under argon atmosphere, and then cooled to room temperature. 5mmol NH4F was added, and the mixture was heated to 305°C under vacuum, kept warm for 45min under argon atmosphere, and then cooled to room temperature. Excess ethanol was added, and the mixture was centrifuged at 10000rpm for 15min. After removing the supernatant, the mixture was washed three times with ethanol, acetone, and cyclohexane in sequence to obtain CsLu of this example. (1-x-y) Yb x Er y F z Nanoparticles, the obtained nanoparticles have a size and a NIR-II region fluorescence of 1530nm, Figure 7 Its fluorescence spectrum.
[0065] The above fluorescence spectrum results indicate that the material of the present invention has a NIR-II fluorescence emission peak, which is conducive to high-resolution near-infrared fluorescence imaging, thereby accurately guiding tumor tissue resection.
[0066] Example 5
[0067] This example is used to explore the effect of the feed ratio of sensitizer Yb and activator Er on the luminescence intensity of the obtained nanoparticles. Specifically, different from Example 1, the amount of Yb(Ac)3 was adjusted to 0.18mmol, 0.38mmol, 0.68mmol, and 0.98mmol respectively under the condition that the amount of Er(Ac)3 remained unchanged (0.02mmol), so that the ratio of Yb(Ac)3 to Er(Ac)3 was 9:1, 19:1, 34:1, and 49:1 respectively. The amount of Er(Ac)3 was adjusted to 0.02mmol, 0.10mmol, and 0.20mmol respectively under the condition that Yb(Ac)3 remained unchanged (0.18mmol), so that the ratio of Yb(Ac)3 to Er(Ac)3 was 9:1, 9:5, and 9:10 respectively. Nanoparticles under different feed ratios of sensitizer Yb and activator Er in this example were obtained, and their luminescence intensity was tested. The results are shown in Tables 1, 2 and 3. Figure 8 , Fig. 9 shown.
[0068] Table 1
[0069] Yb and Er feed ratio / (x:y) Luminous intensity (normalized intensity) 9:1 1.00 19:1 0.88 34:1 0.70 49:1 0.64
[0070] Table 2
[0071] Yb and Er feed ratio / (x:y) Luminous intensity (normalized intensity) 9:1 1 9:5 0.11 9:10 0.08
[0072] From Table 1, Table 2 and Figure 8 , Fig. 9 It can be seen that when the Er dosage is constant, as the Yb ratio increases, the fluorescence intensity at 1532nm gradually decreases; when Yb is constant, as the Er ratio increases, the fluorescence intensity at 1532nm also shows a significant downward trend. Therefore, it is necessary to strictly control the feed ratio of sensitizer Yb and activator Er to obtain the optimal luminescence intensity.
[0073] Example 6
[0074] This example is used to explore the effect of the ratio of Ln(Ac)3, Cs2CO3 and NH4F on the luminescence intensity of the obtained nanoparticles. Specifically, different from Example 1, the ratio of Ln(Ac)3, Cs2CO3 and NH4F was adjusted to 2:3:12, 1:1:5, 6:1:20 and 4:1:14 respectively. The remaining steps and processes were all referred to Example 1. Nanoparticles with different ratios of Er(Ac)3, Yb(Ac)3, Cs2CO3 and NH4F in this example were obtained, and their luminescence intensity was tested. The results are shown in Table 2 and Table 2. Fig.10 shown.
[0075] Table 3
[0076] <![CDATA[Ln(Ac)3:Cs2CO3:NH4F]]> Luminous intensity (normalized intensity) 2:3:12 0.05 1:1:5 0.06 6:1:20 0.04 4:1:14 1
[0077] From Table 3 and Fig.10 It can be seen that the luminescence intensity changes greatly with the change of the ratio of Ln(Ac)3:Cs2CO3:NH4F. This is because the change of the ratio of Ln(Ac)3:Cs2CO3:NH4F will cause the change of the lattice structure and then cause the change of fluorescence intensity.
[0078] Example 7
[0079] This example is used to explore the effect of high temperature insulation temperature on the morphology of the obtained nanoparticles. Specifically, the difference from Example 1 is that the insulation temperatures in step 1) are adjusted to 275°C, 285°C, 295°C, and 315°C, respectively. The remaining steps and processes are all based on Example 1. The nanoparticles of this example under different high temperature insulation time conditions are obtained. The transmission electron microscopy images are as follows. Fig.11 As shown, it can be seen that the material morphology obtained when the temperature is 285°C is the most regular, and the regular morphology is conducive to the stability of the material's luminescence properties.
[0080] In summary, the present invention combines CsLu (1-x-y) Yb x Er y F z The NIR-II luminescence properties of nanoparticles and the good immune escape and tumor targeting of cancer cell membranes led to the design of CsLu coated with cancer cell membranes. (1-x-y) Yb x Er y F z Nanoparticles, which can be used to perform NIR fluorescence imaging of tumors and guide surgical removal of tumors;
[0081] Compared with existing visible region and NIR-I region fluorescent materials, the present invention has a NIR-II fluorescence emission peak, which is conducive to high-resolution near-infrared fluorescence imaging, thereby accurately guiding tumor tissue resection;
[0082] Compared with organic materials, the present invention has a longer luminescence lifetime, higher light stability and biocompatibility, and is not easily photobleached.
[0083] Compared with other targeting materials, such as HA, polypeptides, etc., the cancer cell membrane of the present invention has the unique immune escape ability and homologous binding ability of cancer cells, and has better coating effect and better water stability, so that it has a better accumulation effect in tumor tissue.
[0084] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.
Claims
1. A homologous targeted NIR-II region fluorescence imaging nanoplatform, Features: include, CsLu (1-x-y) Yb x Er y F z The nanoparticles are the luminescent centers. After being treated to be water-soluble, the cancer cell membrane is coated on their surface by extrusion, thus forming a homologous targeted NIR-II region fluorescence imaging nanoplatform. Among them, the CsLu (1-x-y) Yb x Er y F z In the nanoparticles, the value of x is 0-0.98, the value of y is 0.02-0.98, and the value of z is 4-7.
2. The homologous targeted NIR-II region fluorescence imaging nanoplatform as claimed in claim 1, Features: The cancer cell membrane and CsLu (1-x-y) Yb x Er y F z The mass ratio of the nanoparticles is 0.5 to 2:
1.
3. The homologous targeted NIR-II region fluorescence imaging nanoplatform according to any one of claims 1 or 2, Features: The cancer cell membranes include mouse breast cancer cell membranes and mouse colon cancer cell membranes.
4. The method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform according to any one of claims 1 to 3, Features: include, Lu salt, Yb salt, Er salt, Cs 2 CO 3 , oleic acid, oleylamine and octadecene were mixed and heated under vacuum to form a transparent solution, kept warm under argon atmosphere, and then cooled to room temperature. NH 4 F is subjected to a synthesis reaction, and after the reaction is completed, it is washed to obtain CsLu (1-x-y) Yb x Er y F z Nanoparticles, the CsLu (1-x-y) Yb x Er y F z In the nanoparticles, the value of x ranges from 0 to 0.98, the value of y ranges from 0.02 to 0.98, and the value of z ranges from 4 to 7; LqCy (1-x-y) Yb x Er y F z The nanoparticles are dissolved in a nonpolar or medium-polar solvent, to which NH 2 -PEG 2000 -DSPE, ultrasonic mixing, to obtain water-soluble CsLu (1-x-y) Yb x Er y F z Nanoparticles; The extracted cancer cell membrane was mixed with CsLu (1-x-y) Yb x Er y F z The nanoparticles were mixed in PBS, sonicated in a water bath, and repeatedly extruded by an extruder to obtain a homologous targeted NIR-II region fluorescence imaging nanoplatform.
5. The method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform according to claim 4, Features: The salt includes an Ac salt or a Cl salt.
6. The method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform according to claim 4, Features: The molar ratio of the Yb salt to the Er salt is 9-19:1-5, and the Lu salt, Cs 2 CO 3 NH 4 The molar ratio of F is 1-4:1-3:5-14.
7. The method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform according to claim 4, Features: When the amount of oleic acid is 6-15 mL, the corresponding amount of oleylamine is 0-4 mL, and the amount of octadecene is 10-15 mL.
8. The method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform according to claim 4, Features: The reaction temperature of the synthesis reaction is 285° C. to 315° C., and the reaction time is 45 to 60 minutes.
9. The method for preparing the homologous targeted NIR-II region fluorescence imaging nanoplatform according to claim 4, Features: The non-polar or medium-polar solvent includes one of acetone, tetrahydrofuran and cyclohexane.
10. Use of the homologous targeted NIR-II region fluorescence imaging nanoplatform as claimed in any one of claims 1 to 3 in tumor imaging.
